Systemic Oral Azoles Segment is Expected to Drive the Growth of the Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market by Type

According to the latest study on ‘Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class, Route of Administration, Distribution Channel, and Country,’ the Asia Pacific Systemic Aspergillosis and Systemic Candidasis market was valued at US$ 1,437.77 million in 2019 and is projected to reach US$ 2,030.54 million by 2027; it is expected to grow at a CAGR of 4.5% during 2020–2027. The report highlights the trends prevailing in the Asia Pacific systemic aspergillosis and systemic candidasis market and the factors driving the market along with those that act as deterrents to its growth.

Based on type, the systemic aspergillosis and systemic candidasis market is segmented voriconazole, liposomal, amphotericin B, systemic oral azoles, topical, antifungal agents, and others. In 2019, the systemic oral azoles segment accounted for the largest share of the Asia Pacific systemic aspergillosis and systemic candidasis market. The growth of the segment attributes to the to rise in prevalence of fungal diseases is among the primary factors contributing to the dominance of the segment in the Asia Pacific systemic aspergillosis and systemic candidasis market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the Asia Pacific region. Systemic aspergillosis and systemic candidiasis are the types of fungal infections. Molds cause the aspergillosis infection and majorly affects the respiratory tract of an individual. In addition it is a severe pulmonary infection caused by Aspergillus, a common fungus that affects people with weakened immune systems or lung diseases. Moreover, severe fungal infections occur due to other health problems, including AIDS, asthma, cancer, organ transplantation, and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal treatment; however, this is often delayed or unavailable leading to death, severe chronic illness, or blindness. For instance, Systemic aspergillosis and systemic candidiasis are the types of fungal infections. Molds cause the aspergillosis infection and majorly affects the respiratory tract of an individual. It is also a severe pulmonary infection caused by Aspergillus, a common fungus that affects people with weakened immune systems or lung diseases. Moreover, severe fungal infections occur due to other health problems, including AIDS, asthma, cancer, organ transplantation, and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal treatment; however, this is often delayed or unavailable, leading to death, severe chronic illness, or blindness. For instance, according to the journal of Fungi published in March 2017, HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma, and the increasing incidence of cancers are the primary drivers of fungal infections in both developed and developing countries globally.

The incidences of human fungal infections are continuously rising. The rise in the incidence of fungal infections is due to new fungal pathogens contaminants and established pathogens with exalted virulence factors, and modified pathogenicity is a cause for the rise in the infections. However, fungal infections are underreported due to different factors such as different clinical presentations, inadequate laboratory confirmation, limited treatment options, and other such factors. In the Asia Pacific regions, there are many hot and humid locations. The people in such climates are estimated to have poor hygienic practices, previous family history, livestock contact, prolonged work hours. These are among the risk factor for developing fungal infections.

Novartis AG, Sanofi, Pfizer Inc., Merck & Co., Inc., Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plc., Abbott, Cipla Inc., Enzon Pharmaceuticals, Inc, are among the prominent players present in the systemic aspergillosis and systemic candidasis market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in July 2018 Pfizer Inc. and Basilea Pharmaceutical Ltd. an international have entered into an agreement whereby Pfizer will be granted the exclusive commercialization rights in Europe to CRESEMBA a novel anti-fungal treatment for adult patients with diagnosed invasive aspergillosis and mucormycosis, two serious infections associated with high morbidity and mortality among immunocompromised patients.

The report segments the Asia Pacific systemic aspergillosis and systemic candidasis market as follows:

By Type

• Systemic Oral Azoles
• Voriconazole
• Liposomal Amphotericin B
• Topical Antifungal Agents
• Others

By Application

• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Chronic Pulmonary Aspergillosis (CPA)
• Gastrointestinal Candidiasis
• Genitourinary Tract Candidiasis
• Others

By Country

• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific